Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1

Bibliography

• Williams R. Global challenges in liver disease. Hepatology 2006;44(3):521-6
   PubMed Web of Science ®Google Scholar
• Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009;50(6):1750-5
   PubMed Web of Science ®Google Scholar
• CDC urges universal hepatitis C screening for baby boomers. Harv Womens Health Watch 2012;19(12):1, 8
   Google Scholar
• Vutien P, Kim Y, Brooks L, et al. Low treatment rates and suboptimal treatment completion rates to hepatitis C virus (HCV) therapy: a real-world analysis of a large US cohort. Gastroenterology 2014;146(5 Suppl 1):S-920
   Google Scholar
• Nguyen LH, Nguyen MH. Systematic review: asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 2013;37(10):921-36
   Google Scholar
• Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42
   PubMed Web of Science ®Google Scholar
• Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138(2):513-21; 521 e1-6
   PubMed Web of Science ®Google Scholar
• Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136(1):138-48
   PubMed Web of Science ®Google Scholar
• Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012;26(4):401-12
   PubMed Web of Science ®Google Scholar
• Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23-30
   PubMed Web of Science ®Google Scholar
• Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47(4):484-91
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone JJr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360(18):1827-38
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867-77
   PubMed Web of Science ®Google Scholar
• Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;369(7):678-9
   PubMed Web of Science ®Google Scholar
• Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310(8):804-11
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384(9956):1756-65
   PubMed Web of Science ®Google Scholar
• Sofia MJ, Bao D, Chang W, et al. Discovery of a beta-d-2’-deoxy-2’-alpha-fluoro-2’-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010;53(19):7202-18
   PubMed Web of Science ®Google Scholar
• Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1 through 6 HCV-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014;59(12):1666-74
   PubMed Web of Science ®Google Scholar
• Rose L, Bias TE, Mathias CB, et al. Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection. Ann Pharmacother 2014;48(8):1019-29
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs 2014;23(4):561-71
   PubMed Web of Science ®Google Scholar
• Link JO, Taylor JG, Xu L, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014;57(5):2033-46
   PubMed Web of Science ®Google Scholar
• German P, Moorehead L, Pang P, et al. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-Uninfected female subjects. J Clin Pharmacol 2014;54(11):1290-8
   PubMed Web of Science ®Google Scholar
• Mogalian E, Mathias A, Yang JC, et al. The pharmacokinetics of ledipasvir, an HCV specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment. Hepatology 2014;60(Suppl 1):1128A-61A
   Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370(20):1889-98
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483-93
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Gruener D, Hill JM, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012;57(1):24-31
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383(9916):515-23
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370(20):1879-88
   PubMed Web of Science ®Google Scholar
• Gordon SC, Fried MW, Kwo P, et al. No differences in the efficacy of fixed-dose combination ledipasvir/sofosbuvir in patients according to fibrosis stage determined by liver biopsy or laboratory biomarker in phase 3 clinical trials. Hepatology 2014;60(Suppl 1):1128A-61A
   Google Scholar
• Sarrazin C, Dvory-Sobol H, Svarovskaia E, et al. Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir ± RBV. Hepatology 2014;60(Suppl 1):1128A-61A
   Google Scholar
• Welzel TM, Herrmann E, Marcellin P, et al. On treatment HCV RNA as a predictor of virologic response in the ledipasvir/sofosbuvir phase 3 program for HCV genotype 1 infection: analysis of the ION-1. Hepatology 2014;60(Suppl 1):1128A-61A
   Google Scholar
• Bouliere M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of > 500 patients with compensated cirrhosis treated with ledip-asvir/sofosbuvir with or without ribavirin. Hepatology 2014;60(Suppl 1):236A-41A
   Google Scholar
• Flamm SL, Everson GT, Charlton M, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014;60(Suppl 1):317A-21A
   Google Scholar
• Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology 2014;60(Suppl 1):200A-3A
   Google Scholar
• Wyles DL, Pockros P, Yang JC, et al. Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks. Hepatology 2014;60(Suppl 1):317A-21A
   Google Scholar
• Townsend K, Osinusi A, Nelson A, et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on or off antiretroviral therapy: results from the NIAID ERADICATE trial. Hepatology 2014;60(Suppl 1):236A-41A
   Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Engl J Med 2014;370(3):211-21
   PubMed Web of Science ®Google Scholar